Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients. The company is built on a foundation of scientific rigor to overcome biological challenges in clinically translatable pathways, exemplified by the first decoy-resistant interleukin-18 (IL-18). By unlocking the potential of IL-18, Simcha is developing its lead program (ST-067) as monotherapy and in combination with potentially several other anticancer agents. ST-067 is currently being studied in a Phase 1/2 clinical trial, in patients with solid tumors and who have progressed on other immunotherapeutic agents. Beyond IL-18, the company’s underlying approach to immune-biology and cytokine engineering has broader potential to support disease-modifying therapeutic options for a range of significant diseases.
Company Details
- Employees
- 15
- Address
- New Haven, Connecticut , Us
- in****@****atx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- simchatx.com
- Keywords
- Manager jobs.
- HQ
- New Haven, Connecticut
Simcha Therapeutics Questions
Simcha Therapeutics's website is simchatx.com
Simcha Therapeutics's LinkedIn profile is https://www.linkedin.com/company/simcha-therapeutics
Simcha Therapeutics has
15 employees.
View email and phone details for 15
employees at Simcha Therapeutics.
Simcha Therapeutics's industry is
Biotechnology Research
Simcha Therapeutics's top competitors are
Seranova Bio,
Ariax Bio,
Dispatch Bio,
Stipple Bio,
Osmol Therapeutics,
Septerna,
Attralus,
Bolden Therapeutics,
Thrive Bioscience, Inc.,
Octagon Therapeutics.
Simcha Therapeutics's support email address is info@simchatx.com
Simcha Therapeutics's categories are Biotechnology Research
